Serum Institute of India is supplying 4,000 doses for the first-in-human trial of the ChAdOx1 BDBV vaccine, developed by the University of Oxford. The trial has been conditionally approved by the Medicines and Healthcare products Regulatory Agency and is now recruiting healthy volunteers.